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ically analyzed tumor cells and matched normal epithelium from clinical formalin-fixed paraffin-embedded
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Abstract 
Spontaneously occurring canine oral squamous cell carcinomas (COSCC) are viewed as a useful model for human head and neck 
squamous cell carcinomas (HNSCC). To date however, the molecular basis of COSCC remains poorly understood. To identify 
changes pertinent to cancer cells in COSCC, we specifically analyzed tumor cells and matched normal epithelium from clinical 
formalin-fixed paraffin-embedded specimens using laser-capture-microdissection coupled with RNA-sequencing (RNAseq). Our 
results identify strong contributions of epithelial-to-mesenchymal transition (EMT), classical tumor-promoting (such as E2F, KRAS, 
MYC, mTORC1, and TGFB1 signaling) and immune-related pathways in the tumor epithelium of COSCC. Comparative analyses 
of COSCC with 43 paired tumor/normal HNSCC from The Cancer Genome Atlas revealed a high homology in transcriptional 
reprogramming, and identified processes associated with cell cycle progression, immune processes, and loss of cellular differentiation 
as likely central drivers of the disease. Similar to HNSCC, our analyses suggested a ZEB2-driven partial EMT in COSCC and identified 
selective upregulation of KRT14 and KRT17 in COSCC. Beyond homology in transcriptional signatures, we also found therapeutic 
vulnerabilities strongly conserved between the species: these included increased expression of PD-L1 and CTLA-4, coinciding with 
EMT and revealing the potential for immune checkpoint therapies, and overexpression of CDK4/6 that sensitized COSCC to 
treatment with palbociclib. In summary, our data significantly extend the current knowledge of molecular aberrations in COSCC 
and underline the potential of spontaneous COSCC as a model for HNSCC to interrogate therapeutic vulnerabilities and support 
translation of novel therapies from bench to bedside. 
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Introduction 
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous 
group of epithelial tumors frequent in humans [1–3] . The main challenge 
of HNSCC lies in local invasion into bone and metastatic disease that lead 
to death of about 50% of patients with HNSCC. Recent developments 
in sequencing technologies coupled with state-of-the-art analytical methods 
have unveiled a plethora of mutations and deregulated pathways in HNSCC 
but understanding their impact on tumor development and survival 
necessitates the availability of accurate disease models. Many different disease 
models have been used thus far, all of them with significant drawbacks 
(e.g., [4–6] ). Most notably, a failure to reflect the natural evolution of 
the tumor and its specific interactions with the native stroma implies that 
these models do not fully recapitulate the complexity of naturally occurring, 
spontaneous HNSCC, much of which can heavily influence the course of the 
disease. 
Based on the closely related pathophysiology, spontaneously occurring 
cancers in the domestic dog are increasingly viewed as valuable models 
to promote understanding of cancer biology and identify novel potential 
therapeutic targets [7–9] . In particular, similar tumor types at similar 
locations between dogs and humans offer the possibility to overcome many 
of the limitations of xenograft or genetically modified rodent tumor models. 
This might apply for spontaneous canine oral squamous cell carcinomas 
(COSCC) that have been proposed as models for human HNSCC [10] . 
COSCC are the second most prevalent malignant oral neoplasm in dogs, 
and most often develop on the maxillar or mandibular gingiva at an 
average age of 9 years [11] . Nontonsillar COSCC display aggressive locally 
invasive behavior also frequently invading bone, but are slow to metastasize, 
which generally leads to a good prognosis following treatment, provided 
they are detected early and excised with sufficient surgical margins [12] . 
Local recurrence and invasion are the major problems, with destruction 
of tissue causing massive pain and dysfunction in affected patients [11] . 
The relatively high prevalence of COSCC, in conjunction with a large pet 
dog population, results in availability of samples. The shorter lifespan of 
dogs also offers the possibility to complete clinical studies in much shorter 
time than with human patients. Lastly, dogs often closely live with their 
owners, resulting in their exposure to similar environmental carcinogens. 
Therefore, analyzing molecular homologies between HNSCC and COSCC is 
considered a valuable approach to identify key events driving the disease and 
novel targets for pharmacological intervention. Finally, given the metabolic 
similarities that allow extrapolation of toxicity-related preclinical data from 
dogs to humans, spontaneous tumors in dogs could also serve as models to 
accelerate translation of novel therapeutic approaches from bench to bedside. 
To date however, COSCC remain poorly understood on a molecular 
level. Currently, only one single study has analyzed 7 oral COSCC cases –
3 of these with matching normal tissue - using bulk RNAseq to describe 
expression changes occurring in these tumors [10] . Analysis of further patient 
cohorts including matched normal tissue samples is of utmost importance 
to validate these findings and further explore the molecular similarities and 
differences between COSCC and HNSCC. In this context, it is becoming 
increasingly clear that tumors are a very heterogeneous mixture of a variety 
of different cells. In addition to epithelial cancer cells, tumors harbor many 
different types of non-neoplastic cells and varying amounts of extracellular 
matrix. Traditionally, analysis of tumor samples has been performed in bulk, 
meaning that results reflect the mixture of all cells present, not differentiating 
between the epithelial cancer cells and the remaining non-neoplastic cells. 
Thus, this approach complicates the correct attribution of the observed gene 
expression changes either to the cancer cells or to the stromal cells. The 
importance of differentially analyzing tumor cells and the surrounding stroma 
has become increasingly evident recently, also for HNSCC (e.g. [13] ). Hence, 
our group has established a workflow to isolate specific subpopulations of 
cells from archival formalin-fixed paraffin-embedded (FFPE) tissue sections 
by laser-capture microdissection (LCM) followed by RNAseq analysis [14–
17] . Using this approach, we set out to specifically isolate tumor cells and 
matched normal epithelial cells from 10 cases of COSCC in order to analyze 
the molecular underpinnings of COSCC and its resemblance with human 
HNSCC. 
Results 
Transcriptome profiling of laser-capture microdissected tumor and 
matched normal epithelium from clinical COSCC specimens 
To analyze gene expression changes in COSCC, we specifically isolated 
tumor cells and matched normal epithelium from clinical FFPE specimens 
using LCM coupled with RNAseq as previously established [14–17] . 
Representative images of tissue specimens and detailed patient characteristics 
for all cases are shown in Table 1 and Supplementary Figure 1. Unsupervised 
multidimensional scaling using the top 1000 variable genes showed 
separation of tumor samples from normal epithelium, suggesting clear 
differences in gene expression profiles between tumor and normal epithelium 
( Figure 1 A). Indeed, differential expression analysis (FDR < 0.05 and fold 
change > 2) revealed 669 significantly differentially regulated genes between 
tumor and matched normal epithelium, with 340 up- and 329 down- 
regulated genes in tumor cells ( Figure 1 B and Supplementary Figure 1D). 
The full list of deregulated genes can be found in Supplementary Table 1. 
To validate the results from RNAseq, we measured expression of six genes 
(COL1A1, FN1, MMP2, TFPI2, CDK6, and CDK4) that were significantly 
up-regulated in tumor cells compared to normal epithelium by RT-qPCR. All 
of these genes showed significant expression changes consistent with RNAseq 
( Figure 1 C–I). Taken together, these findings demonstrate the validity of 
specifically isolating tumor cells and matched normal epithelium from FFPE 
tissue sections and their analysis by RNAseq and reveal the occurrence of vast 
transcriptional reprogramming in COSCC. 
COSCC are characterized by epithelial-to-mesenchymal transition, cell 
cycle progression and activation of classical tumor-promoting and 
immune-related pathways 
To understand the changes between tumor cells and normal epithelium, 
we performed gene set enrichment analysis (GSEA) of hallmark pathways 
obtained from the MSigDB database ( http://software.broadinstitute.org/ 
gsea). The following processes were significantly enriched (FDR < 0.25) 
in COSCC compared to normal epithelium: epithelial-to-mesenchymal 
transition (EMT), interferon alpha response, E2F targets, interferon gamma 
response, G2M checkpoint, angiogenesis, allograft rejection, coagulation, 
MYC targets, complement, KRAS signaling up, mTORC1 signaling, mitotic 
spindle, apoptosis, inflammatory response, STAT3 signaling, hedgehog 
signaling, STAT5 signaling, apical junction, DNA repair, TNF α signaling 
via NF κB, UV response up, and TGF β signaling ( Figure 1 J). Processes 
that were significantly enriched (FDR < 0.25) in normal epithelium 
include: xenobiotic metabolism, fatty acid metabolism, hem metabolism, 
spermatogenesis, estrogen response early, and KRAS signaling down 
( Figure 1 J). The clear emergence of an EMT signature was further supported 
by a strong down-regulation of the majority of detected keratins in tumor 
compared to normal epithelium, consistent with a loss of squamous cell 
differentiation ( Table 2 ). The 2 exceptions to this are KRT14 and KRT17, 
both of which are heavily up-regulated in the tumor. Hence, COSCC cells 
display marked changes in EMT, cell cycle progression, immune-related 
responses and signaling pathways classically associated with tumor formation. 
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Table 1 
Overview of cases with COSCC included in this study. 
Case no. Age (y.) Breed Sex Localization Degree of Differentiation 
1 5 Bolonka Zwetna f/n Oral cavity (gingiva) Moderately differentiated 
2 10 Collie m Oral cavity (gingiva) Moderately differentiated 
3 10 Poodle m Oral cavity (gingiva) Moderately differentiated 
4 6 American Cocker Spaniel m Oral cavity (tongue) Moderately differentiated 
5 14 West Highland White Terrier m Oral cavity Well-differentiated 
6 14 West Highland White Terrier f/n Oral cavity Moderately differentiated 
7 7 Long-Haired Collie f/n Oral cavity (gingiva) Poorly differentiated 
8 15 West Highland White Terrier f/n Oral cavity (gingiva) Moderately differentiated 
9 12 Cairn Terrier m Oral cavity (gingiva) Moderately differentiated 
10 10 n.d. m Oral cavity (gingiva) Moderately differentiated 
age = age at excision of tumour; f/n = female, neutered; m = male; n.d. = not disclosed. 
Figure 1. Transcriptome analysis of tumor cells and matched normal epithelium from 10 cases of canine oral squamous carcinoma. (A) Multidimensional 
scaling of tumor cells and normal epithelium isolated from canine oral squamous carcinoma using top 1000 variable genes. Each dot represents a sample, 
hence there are 20 dots in total (10 tumor and 10 normal), and distances between the dots in 2D approximate the log2 fold changes between the samples 
in multidimensional gene expression space. We used the top 1000 highly variable genes in the MDS analysis. (B) Volcano plot highlighting differentially 
expressed genes in tumor cells compared to normal epithelium, using |FC| > 2 and FDR < 0.05 as cut-off values. (C–H): Expression levels of (C): COL1A1; 
(D): FN1; (E): MMP2; (F): TFPI2; (G): CDK6; (H): CDK4 as detected by qRT-PCR in normal or tumor epithelium, respectively. Values are mean values 
±SEM, normalized to expression levels in tumor cells. n = 3–5 pairs. P values were calculated using student’s t test with significance cutoff set at P = 0.05. I) 
Summary of the expression trends as detected by RNAseq and RT-qPCR. J) Gene-set enrichment analysis of hallmark gene sets deregulated between tumor 
and normal tissue. Hallmarks with FDR < 0.25 are shown. Positive normalized enrichment score (NES) indicates enrichment in tumor compared to normal 
tissue. 
High-grade homology in transcriptional reprogramming between 
COSCC and HNSCC identifies drivers of the disease 
To date there is only very limited data with respect to transcriptional 
reprogramming in COSCC, which strongly limits our understanding 
regarding the extent of molecular homology and difference between COSCC 
and HNSCC. To perform an unbiased comparative analysis of expression 
changes between HNSCC and COSCC, we made use of the TCGA data 
for HNSCC. Since our analysis of COSCC was based on comparing 
matched tumor/normal samples, we aimed for the same setup in the HNSCC 
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Table 2 
Expression changes of selected Keratin genes pertaining to squamous differentiation. 
Identifier gene_name log2 Ratio P Value FDR 
ENSCAFG0 0 0 0 0 0 07208 KRT76 −6.469 1.04E-127 8.51E-124 
ENSCAFG0 0 0 0 0 0 07233 KRT71 −5.807 3.05E-77 8.35E-74 
ENSCAFG0 0 0 0 0 016017 KRT24 −5.62 1.48E-70 3.03E-67 
ENSCAFG0 0 0 0 0 0 07322 KRT3 −3.363 6.91E-19 2.27E-16 
ENSCAFG0 0 0 0 0 025402 KRT78 −3.173 2.47E-15 6.75E-13 
ENSCAFG0 0 0 0 0 015999 KRT23 −2.824 3.87E-08 4.13E-06 
ENSCAFG0 0 0 0 0 023449 KRT13 −2.816 2.37E-38 2.44E-35 
ENSCAFG0 0 0 0 0 0 07328 KRT80 −2.662 1.62E-08 1.88E-06 
ENSCAFG0 0 0 0 0 023529 KRT15 −1.929 2.71E-13 6.02E-11 
ENSCAFG0 0 0 0 0 0 07204 KRT79 −1.798 0.001153 0.02762 
ENSCAFG0 0 0 0 0 031250 KRT14 1.929 9.68E-08 9.03E-06 
ENSCAFG0 0 0 0 0 0 07595 KRT17 3.767 8.02E-17 2.35E-14 
Differentially regulated genes with a P -Value ≤ 0.01 and false-discovery rate (FDR) ≤ 0.1 were considered. Negative 
log2 Ratio values denote genes significantly down-regulated in tumor cells, while positive values are significantly up- 
regulated in tumor cells compared to the matched normal epithelium. 
data. One dataset (GSE62944) matched the criteria containing paired 
tumor/normal samples for all patients of tumors from different anatomical 
sites of the oral cavity (Supplementary Figure 2). We hypothesized that 
if there was molecular homology in transcriptional reprogramming of the 
tumor cells between the 2 species, up-regulated genes in human tumors 
should on average also show up-regulation in canine tumors. Similarly, 
down-regulated genes in human tumors should on average also demonstrate 
down-regulation in canine tumors. We tested this hypothesis using 
competitive (GSEA-like, Figure 2 A and B) and self-contained (QuSAGE, 
Figure 2 C) gene set testing. Reassuringly, we found strong agreement in 
the differential expression profiles between the 2 datasets, suggesting high- 
grade homology in transcriptional reprogramming between HNSCC and 
COSCC. 
To further explore the genes whose expression was highly correlated 
between HNSCC and COSCC, we analyzed the leading edge of the 
up- and down-regulated genes (i.e., the genes that were highly similarly 
deregulated in both species) derived from GSEA analysis. The up-regulated 
leading edge consisted of 283, and the down-regulated leading edge of 
249 genes ( Figures 2 A and B, and Supplementary Tables 2 and 3). Over- 
representation analysis of Gene Ontology biological processes among the 
leading edge up-regulated genes (as determined in Figure 2 A) revealed the 
majority of genes to be involved in processes associated with cell cycle and 
division, immune processes, and extracellular restructuring ( Figure 2 D). 
Examination of the genes belonging to the down-regulated leading edge 
revealed the majority of these genes to be involved in processes associated 
with epithelial cell and tissue differentiation and development, and metabolic 
processes ( Figure 2 E). Interestingly, expression of one of the central EMT 
drivers, ZEB2, was significantly up-regulated in tumors compared to normal 
epithelium ( Figure 2 F; P -value 0.0065), while expression of other typical 
EMT regulators such as ZEB1, SNAI1, SNAI2, SNAI3 and TWIST2 either 
did not change, or could not be detected at a sufficient level (Supplementary 
Table 1). This very specific up-regulation of ZEB2 might suggest the presence 
of a partial EMT program in COSCC. Previous studies have demonstrated 
a significant association between EMT and expression of PD-L1 (CD274), 
one of the key molecules that block anti-tumor immune response, in 
HNSCC [22] . Accordingly, RNAseq revealed a significant increase in CD274 
in canine tumor cells (Log2 fold-change = 1.527, P -value = 0.001), which 
was validated by qRT-PCR ( Figures 2 G and H). Moreover, expression 
of the immune inhibitory checkpoint receptor CTLA-4 (CD152) was 
significantly increased in tumor compared to normal epithelium (Log2 fold- 
change = 0.7106, P -value = 0.013) ( Figure 2 I). Thus, there is an increased 
expression of the immune inhibitory molecules PD-L1 and CTLA-4 in 
COSCC tumor cells that also display active EMT signaling, suggesting 
that COSCC patients could potentially benefit from immune checkpoint 
inhibitor therapies. 
Taken together, these findings reveal a significant overlap between 
HNSCC and COSCC both in terms of deregulated genes and associated 
biological pathways, supporting the presence of extensive molecular 
homology between COSCC and HNSCC. As such, these data identify a 
partial EMT program and cell cycle progression as conserved central drivers 
of the disease in COSCC and reveal the potential for immune checkpoint 
inhibitor therapies for treatment of COSCC. 
Identification of CDK4/6 inhibition as therapeutic vulnerability of 
COSCC 
There is great interest in identification of therapeutic vulnerabilities in 
both HNSCC and COSCC that could be used to complement and/or reduce 
the extent of surgical intervention. To explore this avenue, we took advantage 
of the Expression2Kinases (X2K, [24] ) computational framework to shed 
light on the upstream regulators likely responsible for observed patterns in 
the COSCC gene expression data. X2K aims to identify candidate genes 
that are likely responsible for observed changes in mRNA expression, which 
could be exploited as therapeutic targets. Figure 3 A shows the top kinases 
upstream of differentially expressed genes identified in COSCC compared 
to normal epithelium as revealed by X2K. The second hit, CDK4 caught 
our attention as inhibitors of CDK4/6 are readily available and already in 
clinical use [25] . An involvement of CDK4 was in agreement with the strong 
enrichment of E2F signaling as revealed by GSEA ( Figure 1 J), a regulator 
of cell cycle progression via phosphorylation of RB by cyclin D-CDK4/6. 
Given our findings on CDK4/6 and E2F signaling, we analyzed the levels 
of CDK4, CDK6 and Cyclin D1 in COSCC. Indeed, cyclin dependent 
kinase 6 (CDK6) was significantly overexpressed in tumor cells compared to 
normal epithelium (log2 fold change = 1.854, P -value = 0.007, Figure 3 B), 
which was validated by RT-qPCR ( Figures 1 G and I). Similarly, qRT-PCR 
validation showed significantly elevated CDK4 in tumor cells ( Figures 1 H 
and I), albeit not significant in RNAseq (Log2 fold change = 0.9817, P - 
value = 0.115, Figure 3 C). Cyclin D1 expression did not significantly differ 
between normal and tumor cells in RNAseq ( Figure 3 D). Both CDK4 and 
CDK6 can be pharmacologically inhibited by clinically approved inhibitors, 
such as palbociclib, in humans. Importantly, canine and human CDK4 and 
CDK6 are highly conserved, suggesting that palbociclib could be used to 
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Figure 2. COSCC and HNSCC display a high grade of homology. (A and B) Competitive gene set testing to compare COSCC to HNSCC. GSEA-like 
running sum statistic depicting the location of (A) up-regulated and (B) down-regulated genes in HNSCC on a ranked list of genes in COSCC compared 
to normal. Permutation P -values were calculated by fgsea package. (C) Self-contained gene set testing (QuSAGE method) to assess the average differential 
expression of HNSCC gene sets (i.e., up- and down-regulated genes in HNSCC) in COSCC. X-axis demonstrates mean fold change expression in tumor 
compared to normal in COSCC (HNSCC data obtained from GSE62944). Y-axis indicates the distribution of fold change expression within each set. P - 
values were calculated by comparing mean fold change to fold change of 1 using Welch’s t -test. (D-E) Hypergeometric P -values indicating enrichment of 
Gene Ontology biological processes (GObp) among the leading edge up-regulated (D) and down-regulated (E) genes as revealed by competitive gene testing 
in panels A and B. ( F) Levels of ZEB2 in normal epithelium and tumor cells as detected by RNAseq. (G): Levels of CD274/PD-L1 as detected by RNAseq 
in normal and tumor epithelium, respectively. (H): Levels of CD274/PD-L1 as detected by qRT-PCR in normal and tumor epithelium, respectively. P -values 
were calculated using student’s t test with significance cutoff set at P = 0.05. (I): Levels of CD152/CTLA-4 as detected by RNAseq in normal and tumor 
epithelium, respectively. COSCC, canine oral squamous cell carcinomas; HNSCC, head and neck squamous cell carcinomas. 
inhibit activity of CDK4/6 also in canine tumors. This hypothesis was further 
supported by the enrichment of genes encoding for proteins that interact with 
palbociclib, in COSCC compared to normal epithelium ( Figure 3 E, GSEA 
P -value < 0.001). 
Inspired by these findings, we set out to investigate whether COSCC cells 
were sensitive to palbociclib in vitro. To assess this, 2 cancer cell lines directly 
derived from independent cases of COSCC (termed SCC1 and CoSCC, 
respectively), and a canine stromal cell line that served as nonepithelial control 
(termed DUS) were exposed to different concentrations of palbociclib in 
vitro. Human HeLa cells, known to have a high IC50 for palbociclib, and 
human MDA-MB-231 cells, known for a lower IC50, served as negative 
and positive controls, respectively [28] . As expected, HeLa cells showed 
a markedly higher IC50 than MDA-MB-231 cells ( Figures 3 F and G). 
Interestingly, both COSCC cell lines were highly sensitive to palbociclib, 
whereas growth of the canine stromal cell line DUS was hardly inhibited 
( Figures 3 F and G). Of note, sensitivity of the 2 COSCC cell lines markedly 
exceeded that of the human MDS-MB-231 cells. Western blot analysis 
confirmed elevated levels of CDK6 and Cyclin D1 in both SCC1 and CoSCC 
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Figure 3. Identification of CDK4/6 inhibition by palbociclib as therapeutic vulnerability of COSCC. ( A) Top 20 upstream kinases deduced from COSCC 
gene expression data using Expression2Kinases (X2K). CDK4 is the second most enriched kinase revealed by X2K. ( B-D) Levels of CDK6 (B), CDK4 (C) and 
Cyclin D1 (D) mRNA in normal epithelium and tumor cells as detected by RNAseq. (E) GSEA analysis of palbociclib target genes in COSCC compared to 
normal epithelium (GSEA P -value < 0.001). Palbociclib target genes were obtained from the Comparative Toxicogenomics Database (CTD). (F) Sensitivity 
of cell lines to palbociclib treatment. The canine oral squamous cell carcinoma cell lines CoSCC and SCC1, and a canine stromal cell line DUS, as well as 
human HeLa and MDA-MB-231 cells were exposed to increasing concentrations of palbociclib for 72 h, after which the number of surviving cells was assessed 
using the Resazurin assay. The percentage of surviving cells was calculated in relation to control cells exposed to DMSO only. Data shown are mean from n = 6 
independent assays ±SD. The colored lines indicate nonlinear fit IC50 curves for each cell line; purple: DUS, yellow: HeLa, green: MDA-231, dark blue: 
SCC1, light blue: CoSCC. ( G) IC50 values of the cell lines tested in (F). Shown are IC50 and the 95% confidence intervals, as calculated using nonlinear 
regression (curve fit; normalized response with variable slope) from n = 6 independent assays with 4–8 replicates per data point. ( H-J) Western blot of CDK6 
(H), Cyclin D1 (I), and CDK4 (J) levels in the canine cell lines SCC1, CoSCC, and DUS. Tubulin served as loading control. Relative levels of CDK6, Cyclin 
D1, and CDK4 to tubulin, normalized to levels in DUS cells are indicated below the blots. ( K) Cell cycle analysis of SCC1, CoSCC, DUS, HeLa and MDA- 
MB-231 cells after a 24 h treatment with palbociclib. Data shown are mean from n = 6 independent assays ±SEM. Significance was analyzed using Student’s 
two-tailed t test; ∗∗ = P < 0.01, ∗∗∗ = P < 0.001. ( L) Analysis of viable, early and late apoptotic and necrotic CoSCC and SCC1 after a 72 h treatment with 
palbociclib. Data shown are mean from n = 4 independent assays ±SEM. Significance was analyzed using Student’s two-tailed t test; ∗ = P < 0.05, ∗∗ = P < 
0.01, ∗∗∗ = P < 0.001. COSCC, canine oral squamous cell carcinomas; HNSCC, head and neck squamous cell carcinomas; ns = not significant. 
compared to DUS cells, while CDK4 levels were comparable in all 3 cell lines 
( Figure 3 H–J). 
As CDK4/6 are responsible for the G1/S transition of the cell cycle, 
palbociclib treatment is expected to increase the number of cells in G1. 
Accordingly, cell cycle analysis of cells treated with concentrations ranging 
from 0.1 to 1 μM palbociclib for 24 h revealed a significant increase in 
the G1 cell population and a concomitant decrease in S-phase cells in 
the sensitive SCC1 and CoSCC and MDA-MB-231 cells ( Figure 3 K). In 
contrast, the cell cycle of DUS and HeLa cells did not alter upon palbociclib 
treatment, further corroborating the relative insensitivity of these 2 cell lines 
against palbociclib ( Figure 3 K). These findings suggest that the sensitivity 
of COSCC cells towards palbociclib is at least partially mediated through 
induction of a cell cycle arrest. Palbociclib has also been shown to induce 
apoptosis in sensitive cells. To understand whether an increase in apoptosis 
could also contribute to the strong sensitivity of COSCC cells towards 
palbociclib, we measured the rate of early and late apoptotic cells after 
exposure to 0.1 μM palbociclib for 72 h. Clearly, palbociclib induced a 
significant increase in the number of cells both in early and/or late apoptosis, 
and a concomitant decrease in viable cells in CoSCC and SCC1, suggesting 
that the sensitivity of COSCC cells towards palbociclib is driven by a 
combination of G1 arrest and apoptosis ( Figure 3 L). Importantly, as only 
partially viable cells that remain attached to the plates at the time of harvesting 
can be analyzed, these numbers are likely to substantially underestimate the 
extent of late apoptosis. In summary, our results demonstrate that COSCC 
overexpress CDK6 and/or CDK4, which renders them sensitive to induction 
of apoptosis by low doses of palbociclib. Thus, we have identified CDK4/6 
overexpression as a potential therapeutic vulnerability in COSCC that should 
be further interrogated in a clinical setting. Given the current clinical trials 
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addressing palbociclib and other CDK4/6 inhibitors for the treatment of 
HNSCC, these data strongly advocate that homology between COSCC 
and HNSCC extends far beyond similarities in transcriptional signatures, 
and allows interrogation of therapeutic vulnerabilities using COSCC as a 
model for HNSCC, to support translation of novel therapies from bench to 
bedside. 
Discussion 
Here, we present a thorough transcriptome analysis of tumor cells 
and matched normal epithelium isolated from 10 cases of COSCC using 
LCM of FFPE tissue coupled with RNAseq. Our data provide detailed 
insight into transcriptional reprogramming of COSCC and identifies 
strong molecular homologies and therapeutic vulnerabilities shared between 
COSCC and HNSCC. As such, our findings validate and significantly extend 
an earlier analysis that suggested the existence of molecular homologies 
between COSCC and HNSCC [10] that extend far beyond similarities 
in transcriptional signature, provide information about clinically actionable 
targets for the treatment of COSCC, and advocate the interrogation of 
therapeutic vulnerabilities using COSCC as a model for HNSCC to support 
translation of novel therapies from bench to bedside. 
We found wide-ranging molecular homologies between HNSCC and 
COSCC ( Figure 2 ). Strongest overlaps among the up-regulated genes were 
found in processes associated with cell cycle and division, immune processes, 
and extracellular restructuring ( Figure 2 D), whereas overlaps among the 
down-regulated genes centered on epithelial cell and tissue differentiation 
and development, and metabolic processes, suggesting activation of an EMT 
program in COSCC ( Figure 2 E). This was further supported by gene set 
enrichment analysis of COSCC revealing a strong EMT signature ( Figure 1 J). 
EMT is a salient feature of HNSCC that has been recently identified in 
humans and strongly correlated with a more malignant tumor phenotype 
[13] . Further support for the activation of EMT derives from the fact that 
the majority of all detected keratins in tumor cells were down-regulated 
compared to normal epithelium, consistent with a loss of differentiation 
( Table 2 ). In strong contrast to this, KRT14 and KRT17 are both heavily 
up-regulated in COSCC. These 2 are among the top up-regulated keratins 
in HNSCC and other human SCC [ 13 , 18–20 ]. Expression of both KRT14 
and KRT17 is associated with basal epithelial layers [29] , and it has been 
suggested that high levels of KRT14 and KRT17 are needed to sustain 
a “stem-like” proliferative epidermal cell phenotype [30] . Finally, human 
squamous cell carcinomas are characterized by the expression of KRT14 
and KRT17 [18] . Substantial EMT has also been suggested to occur in 
COSCC [10] . In the context of the present study, expression of one of the 
central EMT drivers, ZEB2, was also significantly up-regulated, while we 
did not detect changes in other typical EMT regulators. This suggests the 
presence of a partial ZEB2-orchestrated EMT program in COSCC, similarly 
to the SNAI2-driven partial EMT in HNSCC, which is clearly distinct 
from full EMT programs or “mesenchymal” tumor signatures derived from 
bulk tumor sequencing [13] . The loss of genes related to cell and tissue 
differentiation is in direct concordance with the observed loss of squamous 
cell differentiation observed in the tumor cells ( Table 2 ), and the top-ranking 
overall hallmark changes in EMT ( Figure 1 J). In contrast to our data, Liu et al. 
identified TWIST1 and SNAI1 to be recurrently overexpressed in COSCC 
[10] . This discrepancy could well derive from the difference in analysis of 
purified tumor epithelia versus bulk tumor (containing tumor stroma), as 
bulk tumor sequencing has been shown to result in more “mesenchymal”, 
likely stroma-derived signatures [13] , and TWIST1 has been shown to be 
expressed predominantly in the activated tumor stroma in breast cancer [31] . 
Even more support for a strong EMT-related reprogramming comes from 
the leading edge down-regulated genes, the majority of which are involved 
in processes associated with epithelial cell and tissue differentiation and 
development, and metabolic processes ( Figure 2 E). Equally , the decrease in 
metabolic processes is in line with a more mesenchymal phenotype that has 
been demonstrated to be more motile but less metabolically active than typical 
epithelial cells [ 13 , 21 ]. Finally, there is a significant correlation between 
EMT and expression of PD-L1 (CD274) and CTLA-4 (CD152), 2 of the 
key molecules that block antitumor immune response, in HNSCC [22] . 
Accordingly, our RNAseq dataset also revealed a significant increase in both 
of these inhibitory molecules in the tumor epithelium. This indicates that 
in COSCC, similar to human tumors, there is increased expression of PD- 
L1 and CTLA-4 that correlates with expression of EMT markers, suggesting 
that patients with COSCC could benefit from immune checkpoint inhibitor 
therapies, in a manner comparable to results from currently ongoing trials 
with HNSCC [23] . It is important to note that the TCGA dataset is built 
on bulk tumor sequencing, which leads to the presence of stroma-derived 
data in contrast to our LCM approach. As such, this could potentially lead to 
an overestimation of mesenchymal-like gene signatures in the TCGA data. 
Given the comparison with canine epithelial data, this is not expected to 
influence the comparative expression changes presented herein. 
HNSCC pathogenesis is strongly associated with loss of TP53 function, 
caused either by direct mutation of TP53 through carcinogens (most 
prominently tobacco smoke or alcohol consumption), or through infection 
with human papillomavirus (HPV), whereby viral protein products bind 
to and inactivate TP53 [1] . Of note, an association between tumors of 
the nasal cavity in dogs and environmental exposure to tobacco smoke 
has been reported, suggesting that the occurrence of tumors in pet dogs 
could potentially act as “sentinel event” for human cancer risk [32] . To 
date, however, it remains unclear whether and to what extent development 
of COSCC is associated with exposure to such harmful environmental 
agents. HPV infection is implicated in development of more than 50% 
of oropharyngeal HNSCC, usually with high levels of HPV detectable in 
affected tumors [1–3] . The contribution of papillomaviruses (PV) to COSCC 
is much less clear [11] . Despite few early reports indicating the presence 
of PV in a limited number of COSCC [33] , normally the levels of canine 
PV detected in COSCC are very low and only present in very few samples 
[10] , or not at all [34] . In our analyses of 10 cases of COSCC, we did 
not find any indication of PV presence in the RNAseq data whatsoever 
(data not shown), supporting previous reports arguing against a role of PV 
as a major contributor to development of COSCC [35] . The involvement 
of TP53 in the development of COSCC is yet under debate. Nuclear 
overexpression of TP53 has been detected in 69% and 35% of the examined 
oral and nonoral canine squamous cell carcinomas [ 33 , 36 ]. Only very few 
studies have analyzed the prevalence of TP53 mutations in COSCC, and 
these only found very few mutations in TP53, suggesting that mutations 
of this gene might contribute less prominently to COSCC [10] . As such, 
due to the small number of analyzed cases, it remains unclear to what 
extent mutations in TP53 contribute to the biology of COSCC. It is 
interesting to note, however, that TP53 has been found to directly repress 
transcription of KRT14 and KRT17, both of which are heavily up-regulated 
in COSCC as discussed above, suggesting an impairment of TP53 activity 
in COSCC [ 37 , 38 ]. Despite some of these differences between COSCC 
and HNSCC, transcriptional reprogramming is highly comparable in the 
2 species, with the E2F-CDK4/6 axis emerging as a salient feature. In 
HNSCC, components of the CyclinD – CDK4/6 pathway are often altered 
through various different mechanisms [1–3] . Indeed, genomic amplification 
of CDK6 has been detected in COSCC [10] , providing a rationale for the 
high CDK6 levels that can be detected in these tumors. This is in line with 
the increased expression of genes related to cell cycle progression, such as 
CDK6 and E2F targets in our analysis, suggesting strong contributions from 
this pathway to COSCC. Along this line, it has been recently demonstrated 
that CDK6 antagonizes functions of TP53 during tumorigenesis, allowing 
for immortalization and outgrowth of primary transformed cells [39] . Hence 
it is tempting to speculate that while the initial molecular trigger for tumor 
formation might differ between the 2 species, both COSCC and HNSCC 
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mechanistically depend on the activation of the CDK6-E2F pathway as 
a trigger to advance the cell cycle, as well as on inactivation of TP53 
to undergo full transformation. In HNSCC, CDK6 overactivation can be 
found in 8% of HPV-negative cases, but not in HPV positive cases [1] . 
Also, in HPV-negative HNSCC, the CDK6-inhibitory factors CDKN2A 
and let-7c are inactivated in 57% and 40% of all cases, while no or little 
inactivation occurs in HPV positive tumors. The reasons for the frequent 
amplification and/or overexpression of CDK6 in COSCC should be further 
analyzed. 
With respect to therapeutic vulnerabilities, activation of the CyclinD 
– CDK4/6 pathway can sensitize tumor cells to CDK4/6 inhibitors in 
HNSCC. Indeed, when combined with cetuximab, the CDK4/6 inhibitor 
palbociclib has shown clinical efficacy in HNSCC in a phase I trial 
[40] and a multicenter phase II trial [41] . Thus, CDK4/6 inhibition is 
currently considered as a viable option for treatment of HPV-unrelated 
HNSCC in humans [ 42 , 43 ]. In line with these findings, several clinical 
trials aiming to analyzing the combination of palbociclib in combination 
with carboplatin or PI3K/mTOR inhibitors in advanced, recurrent or 
unresectable cases of HNSCC and other solid tumors are in progress 
(clinicaltrials.gov: NCT03194373, NCT03065062). Our results strongly 
support the assumption that COSCC heavily rely on CDK4/6-CyclinD 
activation, as evidenced by significant overexpression of CDK4/6 in tumors 
compared to normal epithelium as well as the strong sensitivity of COSCC 
cell lines to palbociclib treatment in vitro ( Figure 3 ). This suggests that 
treatment with palbociclib (or potentially other clinically approved CDK4/6 
inhibitors) could indeed provide a valuable therapeutic option for COSCC, 
especially in cases where surgical resection is difficult. 
Material and methods 
Canine cases included in the study 
The cases included were FFPE diagnostic specimens selected from the 
records of the Swiss Canine Cancer Registry (see also Table 1 for a list of 
all cases) [44] . They were selected based on the requirement that a sufficient 
amount of non-neoplastic epithelium was available on the blocks. The tumors 
consisted of 10 oral, nontonsillar, conventional squamous cell carcinomas 
[45] . One tumor was well-differentiated, eight tumors were moderately 
differentiated, and one was poorly differentiated. 
Laser-capture microdissection and RNA isolation 
Laser-capture microdissection was performed as described in [14] . Areas 
for isolation were defined by a nationally-certified veterinary pathologist, 
and comprised on one side neoplastic epithelial tissues including all levels 
of differentiation present and excluding areas with obvious clusters of 
intraepithelial leukocytes (mainly consisting of neutrophils); on the other 
side they comprised adjacent, non-neoplastic epithelium. RNA from LCM- 
isolates was extracted as previously described [15] . RNA abundance and 
quality were analyzed using the 4200 Tape Station Software using the 
High Sensitivity RNA ScreenTape kit (Agilent Technologies), as detailed in 
Supplementary Table 4. 
Quantitative RT-PCR 
Reverse transcription was performed using the iScript cDNA Synthesis 
Kit (BioRad) according to the manufacturer’s protocol, using a total of 5 ng 
of RNA per reaction, and cDNA was preamplified using the TaqMan PreAmp 
Master Mix (2 ×) (Applied BiosystemsTM) according to the manufacturer’s 
protocol using 14 PCR cycles. RT-qPCR was performed using KAPA PROBE 
FAST qPCR Kit Master Mix (2 ×) Universal reagents (Kapa Biosystems), 
with 2,5 μL cDNA/reaction in a total volume of 10 μL and reactions 
were run in duplicates on the CFX384 Touch Real-Time PCR detection 
system (BioRad). The primer details can be found in Supplementary Table 
5. Quantification of gene expression was performed using the comparative 
CT method and values were normalized against GAPDH, PPIA and B2M as 
endogenous controls. Results were expressed as fold change in mRNA levels 
of tumor compared to normal epithelium. Primers were customized Taqman 
gene expression assays specifically designed to detect the canine isoforms of 
the targeted genes (ThermoFisher Scientific), used at final concentrations 
of 900 nM primers and 250 nM probes, or, for canine GAPDH, purchased 
from Microsynth (Balgach, Switzerland) and used at a final concentration of 
300 nM primers and 200 nM probe. All primer pairs have been validated and 
displayed approximately 100% amplification efficiency. 
RNA sequencing 
RNA sequencing was performed as previously described [15] . Briefly, 
RNA library preparation and depletion of ribosomal RNA was performed 
using the SMARTer Stranded Total RNA-seq Kit Pico Input Mammalian 
(Clontech) with 4 ng input RNA. The libraries were loaded onto an Illumina 
HiSeq5000v4 instrument and subjected to 2 × 126 cycles of paired-end 
sequencing according to standard protocols used at the Functional Genomics 
Centre Zurich (FGCZ). The raw sequencing data have been deposited in the 
European Nucleotide Archive with the primary accession code PRJEB34234. 
Bioinformatics analyses 
The quality of RNAseq reads was assessed with FastQC ( http://www. 
bioinformatics.babraham.ac.uk/projects/fastqc ). Reads were trimmed with 
Trimmomatic [46] (v0.33, 4 bases hard-trimming from the start, and adaptor 
trimming at the end). Trimmed reads were aligned to the reference genome 
and transcriptome (FASTA and GTF files, Ensembl release88, CanFam3.1) 
with STAR [47] version 2.5.1b. Gene expression was quantified using 
the R/Bioconductor package R subread (version 1.24.1) [48] . Genes with 
consistently low counts were filtered out by keeping those with Count Per 
Million (CPM) value above 5.6 in at least 10 libraries. These cutoffs were set 
based on the sequencing depths and experimental design. CPM values were 
computed by “cpm” function from edgeR Bioconductor package (version 
3.24.0) [48] . 
Raw counts were subsequently normalized and adjusted for mean- 
variance trend using the “rlog” function from DESeq2 Bioconductor 
package (version 1.22.0) [49] . Normalized data were then used to 
generate multidimensional scaling plot of distances between gene expression 
profiles with “plotMDS” function from limma Bioconductor package 
(version 3.38.1) [50] . Differential expression analysis was performed using 
DESeq2 Bioconductor package, setting padj = 0.05 and log2FoldChange = 1 
as significance threshold [49] . Shrunken log2foldchange estimates were 
obtained using the original DESeq2 shrinkage estimator. Gene annotation 
(i.e., canine ensembl id to canine gene symbol and canine ensembl id to 
human ortholog mappings) were obtained using biomaRt Bioconductor 
package (version 2.38.0) [51] . GSEA analysis was performed with fgsea 
Bioconductor package (version 1.8.0) [52] with limma’s paired-sample t- 
statistic computed on rlog-normalized data as gene ranking metric, and 
Hallmark gene sets obtained from MSigDB database [53] . Prior to GSEA, 
canine ensembl ids were mapped to human orthologs using biomaRt. If 
a human ortholog was associated with more than one canine ensembl id, 
the ensembl id with maximum variance was selected using the collapseRows 
function from WGCNA R package (version 1.66) [54] . 
Paired tumor/normal RNAseq data from TCGA’s HNSCC subset 
( N = 43) was obtained from Gene Expression Omnibus under GSE62944 
[55] , and differential expression analysis was performed with limma 
Bioconductor package using the voom approach. Setting adj.P.Val = 0.01 
and logFC = 1 as significance threshold, we obtained a HNSCC gene 
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signature comprised of significantly up- or down-regulated genes in human 
tumors compared to their adjacent normal tissue. We next adapted 2 
complementary gene set testing methods to assess the enrichment of HNSCC 
gene signature in COSCC samples. First, we ranked all genes in COSCC 
data based on their fold change expression in tumor vs normal samples. 
We then looked at the enrichment of HNSCC gene signature on this 
ranked list, using GSEA-like running-sum statistic as implemented in 
fgsea Bioconductor package. As the second approach, we used QuSAGE 
(version 2.16.0) [56] , which quantifies activity of HNSCC gene signatures in 
COSCC data with a complete probability density function while accounting 
for inherent gene-gene correlations in the data. We used rlog-normalized 
COSCC counts summarized at the human ortholog level as input for both 
gene set testing methods. Moreover, since both GSEA and QuSAGE test 
for coordinated expression pattern in the data, we examined significantly 
up- and down-regulated HNSCC genes separately. Finally, to further assess 
the biological relevance of genes demonstrating high degree of directional 
homology between the 2 species, we tested for over-representation of Gene 
Ontology terms representing biological processes (GO-bp) among GSEA’s 
leading-edge subsets. Over-representation analysis was performed using the 
GSEA webtool ( https://www.gsea-msigdb.org). Over-represented GO terms 
are ranked based on hypergeometric P -value after correction for multiple 
hypothesis testing according to Benjamini and Hochberg. 
Upstream regulatory kinases potentially responsible for the observed 
expression pattern in COSCC data were identified using Expression2Kinases 
(X2K) software [24] . 
Palbociclib target gene/protein list was obtained from the Comparative 
Toxicogenomics Database (CTD; http://ctdbase.org). GSEA analysis of 
palbociclib target list was performed similar to Hallmark gene sets described 
above. 
Cell culture 
SCC1 cells were derived from a canine oral squamous cell carcinoma 
and were kindly donated by Prof. E. Müller [26] . CoSCC were isolated 
from a gingival squamous cell carcinoma of a 4 years old male Beauceron 
and were a kind gift of Dr. M. Wergin (Division of Radiation Oncology, 
Vetsuisse Faculty, University of Zurich). DUS cells were a kind gift of Prof. 
M. Kowalewski (Veterinary Anatomy, Vetsuisse Faculty, University of Zurich, 
[27] ). HeLa and MDA-MB-231 cells were purchased from ATCC. Cells were 
cultured under standard conditions @ 37 °C in humid atmosphere with 5% 
CO 2 in DMEM high glucose (Sigma) containing 15% FCS (Gibco), MEM- 
Non essential amino acids (Gibco) and antibiotic-antimycotic supplement 
(Gibco). 
Cell treatment and Resazurin assay 
Twenty-four hours before treatment, 1,000 to 2,500 cells were seeded 
in 100 μL complete medium into white-walled 96 well plates. The 
stock solution of palbociclib (10 mM in DMSO; PD0332991 isethionate, 
Sigma) was serially diluted in complete medium to obtain the required 
concentrations and used to replace the seeding medium. After 72 h, 20 μL of a 
stock solution of 0.15 mg/mL Resazurin diluted in PBS was added into every 
well. Sample fluorescence was measured after 2- to 4-h incubations using the 
fluorospectrometer LS-55 from Perkin Elmer set to ex = 560 and em = 590. 
Mean values of 4 to 8 replicate wells were calculated for each treatment point 
and cell line, and normalized to DMSO treated control cells. 
Western blot 
Whole cell extracts for Western blotting were prepared as described 
previously [57] . Proteins were separated on 4% to 20% Tris-Glycine gels 
(Novex) and transferred onto Immobilon-FL Polyvinylidene fluoride (PVDF) 
membranes (Millipore) according to standard procedures (Novex). Blots 
were probed with following antibodies: CDK6 (Novusbio, NBP1–87,262), 
CDK4 (Santa Cruz, sc23896), Cyclin D1 (Santa Cruz, sc8396), and α- 
Tubulin (Sigma, T5168). Secondary antibodies conjugated with Alexa Fluor 
680 (Thermo Scientific) and IRDye 800CW (Li-cor Biosciences) fluorescent 
dyes were used. Detection and quantification were carried out using an 
Odyssey image analysis system (Li-cor Biosciences). 
Cell cycle analysis 
For cell cycle analysis by FACS, trypsinised cells were fixed in ice-cold 
70% ethanol for at least 30 min @ −20 °C. To remove the fixation solution, 
cells were spun 5 min @ 250 rcf @4 °C, and the supernatant was discarded. 
Cells were then resuspended in phosphate buffered saline with 100 μg/mL 
of DNase free RNase A (Sigma) and incubated @37 °C for 30 min, and 
further stained with 10 μg/mL propidium iodide (Sigma). Samples were run 
on a Fortessa (BD Biosciences) and the cell cycle distribution analyzed using 
FlowJo V10.6.1. 
Analysis of apoptosis and necrosis 
Analysis of apoptotic and necrotic cells was performed with the Annexin 
V-FITC Apoptosis Staining/Detection Kit (Abcam, ab14085) according to 
the manufacturer’s protocol. Annexin V is used to label phosphatidylserine 
sites on the membrane surface of apoptotic cells. Propidium iodide (PI) is 
used to label the cellular DNA in necrotic cells where the cell membrane 
has been totally compromised. This combination allows the differentiation 
among early apoptotic cells (annexin V positive, PI negative), late apoptotic 
cells (annexin V positive, PI positive), necrotic cells (annexin V negative, 
PI positive), and viable cells (annexin V negative, PI negative). Briefly, 
cells treated with 0.1 μM palbociclib for 72 h were washed and adherent 
cells tr ypsinised. Tr ypsin was neutralized using serum containing medium, 
500,000 cells were collected by centrifugation, and resuspended in 500 μL 
1X Binding Buffer. 5 μL Annexin V-FITC and 5 μL Propidium Iodide were 
added, and samples were incubated at room temperature for 5 min before 
acquisition with FACS as detailed above. 
Statistical analysis and graphical display of results 
All statistical analysis, calculation and graphical display was performed 
with the program GraphPad Prism ( www.graphpad.com ). Statistical 
significance of gene expression changes detected by RNAseq were calculated 
using a generalized linear model with the patient as secondary factor, i.e., 
paired tests. 
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